EU backs AstraZeneca, Daiichi's ENHERTU

EU backs AstraZeneca, Daiichi's Enhertu for breast cancer treatment post endocrine therapy
The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer treatment for patients who received endocrine therapy but are not suitable for additional hormone treatments.
AstraZeneca Posts Positive Phase III Results for Oral Breast Cancer Drug
In the Phase III SERENA-6 trial, camizestrant—in combination with CDK-inhibitors—beat out current standard-of-care treatments in terms of progression-free survival, according to AstraZeneca.
AstraZeneca, Daiichi Sankyo’s Enhertu recommended for approval in EU
AstraZeneca (AZN) and Daiichi Sankyo’s (DSNKY) trastuzumab deruxtecan has been recommended for approval in the European Union as a monotherapy
AstraZeneca therapy improves breast cancer survival in key trial
Drugmaker AstraZeneca on Wednesday said that its experimental breast cancer treatment improved patient survival without the disease getting worse in a study, a positive outcome in the development of the therapy key to the company's pipeline.
AstraZeneca's metastatic breast cancer treatment gets EU recommendation
AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo said on Friday that the European Medicines Agency (EMA) endorsed ENHERTU for the treatment of metastatic breast cancer. Issuing a positive recommendation, EMA’s Committee for Medicinal Products for Human Use (CHMP)  recommended the marketing authorization for ENHERTUas a monotherapy for the treatment of
Amgen, AstraZeneca announce results from Phase 3 WAYPOINT trial on tezspire
Amgen (AMGN) and AstraZeneca (AZN) announced full results from the Phase 3, registrational WAYPOINT trial demonstrating that TEZSPIRE ...
FierceBiotech4d
AstraZeneca, eyeing $5B peak sales, reports phase 3 breast cancer win for oral SERD
AstraZeneca has advanced its push to make camizestrant a blockbuster, reporting a phase 3 win for the oral SERD at an interim ...
AstraZeneca opens biomethane plant in UK to cut emissions
AstraZeneca has opened a plant to produce biogas from organic waste that will ensure by the end of this year all of its ...
Pharm Exec2d
AstraZeneca’s Camizestrant Shows Survival Improvement for HR-Positive, HER2-Negative Advanced Breast Cancer with Emergent ESR1 Mutations
The Phase III SERENA-6 trial is the first global trial to use a circulating tumor DNA-guided approach to detect endocrine ...
BioPharma Dive3d
AstraZeneca’s next breast cancer drug; Madrigal’s accelerating MASH launch
The British drugmaker claimed success in a first-line breast cancer study. Elsewhere, Rezdiffra sales continued to grow and a ...
FiercePharma3d
BeiGene fleshes out global ambition as Brukinsa surpasses AstraZeneca's Calquence in quarterly sales
On BeiGene’s very first live earnings call, CEO and co-founder John Oyler on Thursday described a “once-in-a-lifetime ...
AstraZeneca reports SERENA-6 trial shows improvement in the primary endpoint
Results from a planned interim analysis of the SERENA-6 Phase III trial showed that AstraZeneca’s (AZN) camizestrant in combination with a ...
Reuters2d
AstraZeneca PLC
UK stocks down for third day as mixed earnings weigh February 20, 2025 AstraZeneca will buy longtime partner FibroGen's China unit for about $160 million to gain rights to its anemia drug in the ...
FiercePharma10d
AstraZeneca pays $160M for FibroGen's China unit, regional rights to roxadustat
AstraZeneca is paying $160 million for FibroGen’s China business, giving the U.K.-based Big Pharma the regional rights to ...
Is AstraZeneca PLC (AZN) the Best Weight Loss Drug Stock to Buy According to Analysts?
We recently published a list of 10 Best Weight Loss Drug Stocks to Buy According to Analysts. In this article, we are going ...